Role of homocysteine in cerebrovascular disease.

Cerebrovascular disease (CVD) is one of the leading causes of morbidity and mortality worldwide and places a huge burden on the health care system. The most common forms of CVD are ischemic cerebrovascular disease (ICVD) and hemorrhagic cerebrovascular disease (HCVD). Since, the treatment, prognosis and rehabilitation of CVD is frustrating, prevention of CVD by properly addressing its modifiable risk factors might be the spearhead to combat the burden. There are several established risk factors associated with CVD, but a newer modifiable risk factor, hyperhomocysteinemia has created a new window for limiting the occurrence of CVD. Homocysteine is potentially vasculotoxic because of its association with endothelial dysfunction and impairment of fibrinolytic system. A total of 248 subjects were included in this case control study. Among them 104 were diagnosed CVD cases (ICVD-59, HCVD- 45) and 144 were age and sex matched healthy controls. Serum total homocysteine was measured in all the study subjects. Mean total homocysteine was found 12.95+/-6.20 micromol/L, 15.55+/-7.35 micromol/L in controls and cases respectively and 15.70+/-7.82 micromol/L, 15.34+/-6.78 micromol/L in ICVD and HCVD respectively. Homocysteine found to be significantly raised in CVD cases compared to controls but sub groups of CVD (ICVD & HCVD) did not differ between themselves with respect to serum homocysteine.